Hepaticojejunostomy stricture
Conditions
Interventions
Endoscopic steroid injection
Sponsors
Ishiwatari Hirotoshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patient with suspected hepaticjejunostomy stricture 2) Patient with >= 20 yo 3) Patient with performance status 1-2 4) Patient without organ dysfunction
Exclusion criteria
Exclusion criteria: 1) Patient with malignant hepaticojejunostomy stricture 2) Patient who cannot stop anti-platelet agent 3) Patient who take steroids or immunosuppressive agents regulary 4) Allergy for triamcinolone 5) Pregnant woman 6) Patient with psychiatric disorder or dementia 7) Patient with severe diabetes mellitus, hypertension, penumonia, digestive tract bleeding, heart failure, angina, or cardial infaction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phase 1: Adverse events rate within 1 week after treatment Phase 2: Hepaticojejunostomy stricture recurrence rate after 1 year after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Phase2 Adverse events rate within 1 week after treatment Hepaticojejunostomy stricture recurrence rate after 2 or 3 year after treatment Late adverse events | — |
Contacts
Public ContactHiroki Sakamoto
Shizuoka Cancer Center
Outcome results
None listed